TABLE 3.
Clonea | ENR concn (μg/ml)b | Mutation distributionc |
Mutation at indicated position |
MIC (μg/ml)d |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GyrA |
ParC |
||||||||||||
2nd step | 3rd step | 4th step | Gly81 | Ser83 | Glu87 | Ser80 | Asp84 | Thr98 | ENR | DAN | MAR | ||
PG45 (GT1 [ST1], GyrB Asp362, 0.25) | 0.5 | 2/7 | Ile | 4 | 8 | 8 | |||||||
1 | 18/18 | Ile | 4 | 8 | 16 | ||||||||
2 | 3/3 | Ile | 8 | 8 | 16 | ||||||||
0.5 | 4/7 | Tyr | 1 | 2 | 2 | ||||||||
1 | 1/7 | Tyr | Tyr | 4 | 8 | 8 | |||||||
1 | 2/7 | Lys | Tyr | 4 | 8 | 4 | |||||||
1 | 1/7 | Phe | Tyr | 4 | 8 | 8 | |||||||
1 | 3/7* | Asp | Tyr | 4 | 8 | 4 | |||||||
2 | 1/3 | Asn | Tyr | 4 | 8 | 4 | |||||||
2 | 2/3 | Asp | Tyr | 4 | 4 | 4 | |||||||
0.5 | 1/7 | 1 | 2 | 1 | |||||||||
1 | 1/4* | Tyr | 2 | 2 | 4 | ||||||||
1 | 1/4* | Phe | 1 | 2 | 2 | ||||||||
1 | 1/4 | Tyr | Tyr | 4 | 8 | 8 | |||||||
1 | 1/4 | Phe | Tyr | 4 | 8 | 8 | |||||||
2 | 1/1 | Tyr | Ile | 16 | 16 | 16 | |||||||
2 | 2/2 | Phe | Tyr | 16 | 16 | 16 | |||||||
15762 (GT4 [ST2], GyrB Asn362, 0.25) | 0.5 | 2/7 | Lys | ND | ND | ND | |||||||
0.5 | 1/7 | 0.5 | 1 | 2 | |||||||||
0.5 | 4/7* | 0.5 | 1 | 2 | |||||||||
1 | 5/8 | Tyr | ND | ND | ND | ||||||||
1 | 1/8 | Phe | ND | ND | ND | ||||||||
1 | 1/8 | Lys | ND | ND | ND | ||||||||
1 | 1/8 | ND | ND | ND | |||||||||
15527 (GT2 [ST3], GyrB Asn362, 4) | 1 | 12/12 | Phe | Asn | 8 | 8 | 16 | ||||||
2 | 36/36 | Phe | Asn | ND | ND | ND | |||||||
8–16 | 5/6 | Phe | Asn | 16 | 8 | 16 | |||||||
8–16 | 1/6 | Phe | Lys | 32 | 8 | 16 | |||||||
15527 (GT3 [ST3], GyrB Asn362, 4) | 1 | 12/12 | Phe | Asn | Arg | 8 | 8 | 16 | |||||
2 | 36/36 | Phe | Asn | Arg | ND | ND | ND | ||||||
8–16 | 1/2 | Phe | Asn | Arg | 16 | 8 | 16 | ||||||
8–16 | 1/2 | Phe | Lys | Arg | 16 | 16 | 32 | ||||||
8619 (GT5 [ST3], GyrB Asn362, 1)e | 0.5 | 22/22 | Phe | 1 | 2 | 2 | |||||||
1 | 3/4 | Phe | ND | ND | ND | ||||||||
1 | 1/4* | Phe | Ile | 32 | 16 | >64 | |||||||
2 | 2/2 | Phe | Ile | 32 | 16 | >64 | |||||||
0.5 | 22/22 | Phe | 1 | 2 | 2 | ||||||||
1 | 12/28 | Phe | ND | ND | ND | ||||||||
1 | 2/28 | Phe | Gly | 8 | 8 | 16 | |||||||
1 | 4/28* | Phe | Asn | 8 | 8 | 16 | |||||||
1 | 10/28* | Phe | Tyr | 8 | 8 | 16 | |||||||
2 | 2/2 | Phe | Asn | 8 | 8 | 16 | |||||||
2 | 2/2 | Phe | Tyr | 8 | 8 | 16 |
Clones are presented by the name of the parental strain, the subtype, the GyrB phenotype, and the enrofloxacin MIC (μg/ml) at the 1st selection step.
Concentration of ENR used to select the different resistant clones during individual passages.
Asterisks indicate clones used to perform the following selection step.
MICs were evaluated on at least one clone of the selected genotype. When no clone was available in broth culture, MIC assays were not performed. ND, not done.
Step 3 was performed using two different clones (same genotype) randomly selected at step 2.